13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • BGB-3111-LTE1

    Acronym: 

    BGB-3111-LTE1

    ACTRN/NCT /ethics: 

    NCT04170283

    Scientific title: 

    Long-term Extension Study of Zanubrutinib (BGB-3111) in Participants With B-cell Malignancies

    Summary of trial and patient characteristics

    Cancer Type Lymphoma
    Trial Type Treatment
    Phase Phase III Tumour Stream Lymphoma
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced, Metastatic or Widespread
    Sex Both Anticipated Start Date 2020-01-21
    Molecular Target Anticipated End Date 2025-12-01
    Cancer Type Lymphoma
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Lymphoma
    Cancer Stage Locally Recurrent or Locally Advanced, Metastatic or Widespread
    Anticipated Start Date 2020-01-21
    Anticipated End Date 2025-12-01

    Trial Summary

    The purpose of this study is to evaluate the long-term safety and efficacy of zanubrutinib in participants with B-cell malignancies who were previously enrolled in an eligible BeiGene study.

    Lay Summary

    Long-term Extension Study of Zanubrutinib (BGB-3111) in Participants With B-cell Malignancies

    Sponsor / Cooperative group

    BeiGene

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Ashford Cancer Centre Research Sue Yeend syeend@adelaidecancercentre.com.au 08 8292 2240 Dr Nicholas Wickham Recruiting